MAPK Signaling
Research Areas
Products Related to MAPK Signaling(660)
- GC48469Moexipril-d5CAS: 1356929-49-1Purity: >99.00%
An internal standard for the quantification of moexipril
- GC48920β-Carboline-1-carboxylic AcidCAS: 26052-96-0Purity: >95.00%
An alkaloid with diverse biological activities
- GC49285Adenosine 5’-methylenediphosphate (hydrate)Purity: >98.00%
An inhibitor of ecto-5’-nucleotidase
- GC49686N-desmethyl Regorafenib N-oxideCAS: 835621-12-0Purity: >90.00%
An active metabolite of regorafenib
- GC50400CC 401 dihydrochlorideCAS: 2250025-96-6Purity: >98%
High affinity JNK inhibitor; also inhibits HCMV replication
- GC60037A-3 hydrochlorideCAS: 78957-85-4Purity: >99.50%
A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases.
- GC60262N-FeruloyloctopamineCAS: 66648-44-0Purity: >98.50%
N-Feruloyloctopamine is an antioxidant constituent. N-Feruloyloctopamine significantly decreases thephosphorylationlevels of Akt and p38MAPK.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC48469 | Moexipril-d5 | 1356929-49-1 | >99.00% | |
An internal standard for the quantification of moexipril | ||||
| GC48652 | Olomoucine II | 500735-47-7 | >98.00% | |
A CDK inhibitor | ||||
| GC48870 | Anagrelide-13C3 | - | >98.00% | |
| GC48920 | β-Carboline-1-carboxylic Acid | 26052-96-0 | >95.00% | |
An alkaloid with diverse biological activities | ||||
| GC49150 | Tpl2 Kinase Inhibitor (hydrochloride) | - | >98.00% | |
A Tpl2 inhibitor | ||||
| GC49186 | O-Demethyl Apremilast | 1384441-38-6 | >95.00% | |
An active metabolite of apremilast | ||||
| GC49241 | Methyl Diethyldithiocarbamate | 686-07-7 | >95.00% | |
An active metabolite of disulfiram | ||||
| GC49265 | PKI (14-22) amide (myristoylated) (trifluoroacetate salt) | - | >98.00% | |
A PKA inhibitor | ||||
| GC49285 | Adenosine 5’-methylenediphosphate (hydrate) | - | >98.00% | |
An inhibitor of ecto-5’-nucleotidase | ||||
| GC49686 | N-desmethyl Regorafenib N-oxide | 835621-12-0 | >90.00% | |
An active metabolite of regorafenib | ||||
| GC49700 | Takeda-6d | 1125632-93-0 | >95.00% | |
| GC49763 | S6K-18 | 1265789-88-5 | >98.00% | |
S6K-18 is a potent and selective p70S6K1 inhibitor with an IC50 of 52 nM. | ||||
| GC50181 | CW 008 | 1134613-19-6 | >98% | |
PKA signaling activator; promotes osteogenesis from hMSCs | ||||
| GC50252 | PF 06260933 dihydrochloride | - | >98% | |
MAP4K4 (HGK) inhibitor; also inhibits MINK and TNIK | ||||
| GC50294 | RMM 46 | 1307896-46-3 | >98% | |
MSK/RSK family kinase inhibitor | ||||
| GC50295 | TL4-12 | 1620820-12-3 | >98.50% | |
Potent MAP4K2 (GCK) inhibitor | ||||
| GC50316 | Org 48762-0 | 755753-89-0 | >98% | |
Selective p38α/β inhibitor; orally bioavailable | ||||
| GC50400 | CC 401 dihydrochloride | 2250025-96-6 | >98% | |
High affinity JNK inhibitor; also inhibits HCMV replication | ||||
| GC50406 | st-Ht31 | 188425-80-1 | >98% | |
Inhibits PKA/AKAP interactions; cell permeable | ||||
| GC50407 | st-Ht31 P | 252869-81-1 | >98% | |
Negative control for st-Ht31 | ||||
| GC50501 | STAD 2 | 1542100-77-5 | >98.00% | |
AKAP disruptor; selectively binds PKA-RII and blocks its interaction with AKAP; cell permeable | ||||
| GC50502 | RI-STAD 2 | - | >98% | |
AKAP disruptor; selectively binds PKA-RI with high affinity and blocks its interaction with AKAP; cell permeable | ||||
| GC60037 | A-3 hydrochloride | 78957-85-4 | >99.50% | |
A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. | ||||
| GC60262 | N-Feruloyloctopamine | 66648-44-0 | >98.50% | |
N-Feruloyloctopamine is an antioxidant constituent. N-Feruloyloctopamine significantly decreases thephosphorylationlevels of Akt and p38MAPK. | ||||